Development and Test of a New Method for Preference Measurement for Multistate Health Profiles

by Kongnakorn, Thitima
Published 2005

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

by Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M
Published 2014-04-01

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria

by Yazid Aoudia, Thitima Kongnakorn, Evie Merinopoulou, Mohamed Said Bettayeb, Sid Ahmed Kherraf

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

by Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, Galsky M
Published 2019-11-01

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal in...

by Thitima Kongnakorn, Christian Eckmann, Matteo Bassetti, Eszter Tichy, Roberto Di Virgilio, Nathalie Baillon-Plot, Claudie Charbonneau
Published 2019-12-01

Improvement of long-term risks of cardiovascular events associated with community-based disease management in Chinese patients of the Xinjiang autonomous region of China

by Yang Li, Cai Minzhang, Ma Minghui, Huang Xinmiao, Liu Laixin, Wang Bei, Zhu Weihai, Zhe Wei, Guan Yumei, Thitima Kongnakorn, Ying Xiao, Siyang Peng, David Hughes, Naranjargal Dashdorj, Thomas Hach
Published 2020-06-01